Treatment of latent tuberculosis infection

Seminars in Respiratory and Critical Care Medicine

Volumn 34, Issue 1, 2013, Pages 67-86

  Vernon, Andrew ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

3HP; isoniazid; latent TB; rifapentine; TB preventive therapy; TB prophylaxis

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE KIDNEY TUBULE NECROSIS; ALCOHOL CONSUMPTION; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL LATENCY; BACTERIAL PHENOMENA AND FUNCTIONS; BACTERIAL SURVIVAL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DISEASE SURVEILLANCE; DORMANCY; DRUG COST; DRUG FATALITY; DRUG RESISTANCE; DRUG TOLERABILITY; EPIDEMIC; FLU LIKE SYNDROME; FOLLOW UP; HEMOLYTIC ANEMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAUNDICE; LATENT TUBERCULOSIS; LIVER TOXICITY; LUPUS LIKE SYNDROME; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RELAPSE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOSIS CONTROL;

ANTITUBERCULAR AGENTS; DISEASE PROGRESSION; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; ISONIAZID; LATENT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84874398517     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0032-1333544     Document Type: Article

References (177)

1. Lobue P., Menzies D. Treatment of latent tuberculosis infection: an update. Respirology: 2010; 15 4 603 622
2. Menzies D., Al Jahdali H., Al Otaibi B. Recent developments in treatment of latent tuberculosis infection. Indian J Med Res: 2011; 133 257 266
3. Leung C. C., Rieder H. L., Lange C., Yew W. W. Treatment of latent infection with Mycobacterium tuberculosis: update 2010. Eur Respir J: 2011; 37 3 690 711
4. Lincoln E. M. The effect of antimicrobial therapy on the prognosis of primary tuberculosis in children. Am Rev Tuberc: 1954; 69 5 682 689
5. Esmail H., Barry C. E. III, Wilkinson R. J. Understanding latent tuberculosis: the key to improved diagnostic and novel treatment strategies. Drug Discov Today: 2012; 17 9-10 514 521
6. Wayne L. G., Hayes L. G. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun: 1996; 64 6 2062 2069 (Pubitemid 26165667)
7. Chao M. C., Rubin E. J. Letting sleeping dos lie: does dormancy play a role in tuberculosis? Annu Rev Microbiol: 2010; 64 293 311
8. McCune R. M., Feldmann F. M., Lambert H. P., McDermott W. Microbial persistence, I: The capacity of tubercle bacilli to survive sterilization in mouse tissues. J Exp Med: 1966; 123 3 445 468
9. McCune R. M., Feldmann F. M., McDermott W. Microbial persistence, II: Characteristics of the sterile state of tubercle bacilli. J Exp Med: 1966; 123 3 469 486
10. Mukamolova G. V., Turapov O., Malkin J., Woltmann G., Barer M. R. Resuscitation-promoting factors reveal an occult population of tubercle Bacilli in sputum. Am J Respir Crit Care Med: 2010; 181 2 174 180
11. Harding J. S., Schreiber H. A., Sandor M. Granuloma transplantation: an approach to study mycobacterium-host interactions. Front Microbiol: 2011; 2 245
12. Gupta A., Kaul A., Tsolaki A. G., Kishore U., Bhakta S. Mycobacterium tuberculosis: immune evasion, latency and reactivation. Immunobiology: 2012; 217 3 363 374
13. Dye C., Scheele S., Dolin P., Pathania V., Raviglione M. C. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA: 1999; 282 7 677 686
14. Bennett D. E., Courval J. M., Onorato I., et al. Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999-2000. Am J Respir Crit Care Med: 2008; 177 3 348 355 (Pubitemid 351198380)
15. Centers for Disease Control and Prevention Targeted tuberculin testing and treatment of latent tuberculosis infarction. MMWR Recc Rep: 2000; 49 No. RR-6 1 51
16. Fox W., Ellard G. A., Mitchison D. A. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis: 1999; 3 10 02 S231 S279 (Pubitemid 29481843)
17. Benator D., Bhattacharya M., Bozeman L., et al. Tuberculosis Trials Consortium Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet: 2002; 360 9332 528 534
18. Ji B., Truffot-Pernot C., Lacroix C., et al. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis: 1993; 148 6 Pt 1 1541 1546 (Pubitemid 24002484)
19. Chapuis L., Ji B., Truffot-Pernot C., O'Brien R. J., Raviglione M. C., Grosset J. H. Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. Am J Respir Crit Care Med: 1994; 150 5 Pt 1 1355 1362 (Pubitemid 24356652)
20. Dhillon J., Dickinson J. M., Sole K., Mitchison D. A. Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide. Antimicrob Agents Chemother: 1996; 40 3 552 555 (Pubitemid 26076566)
21. Lecoeur H. F., Truffot-Pernot C., Grosset J. H. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis: 1989; 140 5 1189 1193 (Pubitemid 19276194)
22. Zhang T., Zhang M., Rosenthal I. M., Grosset J. H., Nuermberger E. L. Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med: 2009; 180 11 1151 1157
23. Zhang T., Li S. Y., Williams K. N., Andries K., Nuermberger E. L. Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med: 2011; 184 6 732 737
24. Landry J., Menzies D. Preventive chemotherapy. Where has it got us? Where to go next? Int J Tuberc Lung Dis: 2008; 12 12 1352 1364
25. American Thoracic Society Preventive treatment in tuberculosis: a statement by the Committee on Therapy. Am Rev Respir Dis: 1965; 91 297 298
26. American Thoracic Society Chemoprophylaxis for the prevention of tuberculosis: a statement by an Ad Hoc Committee. Am Rev Respir Dis: 1967; 96 558 562
27. Ferebee S. H., Mount F. W., Anastasiades A. A. Prophylactic effects of isoniazid on primary tuberculosis in children: a preliminary report. Am Rev Tuberc: 1957; 76 6 942 963
28. Comstock G. W. Isoniazid prophylaxis in an undeveloped area. Am Rev Respir Dis: 1962; 86 810 822
29. Ferebee S. H., Mount F. W., Murray F. J., Livesay V. T. A controlled trial of isoniazid prophylaxis in mental institutions. Am Rev Respir Dis: 1963; 88 161 175
30. Mount F. W., Ferebee S. H. The effect of isoniazid prophylaxis on tuberculosis morbidity among household contacts of previously known cases of tuberculosis. Am Rev Respir Dis: 1962; 85 821 827
31. Ferebee S. H., Mount F. W. Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am Rev Respir Dis: 1962; 85 490 510
32. Ferebee S. H. Controlled chemoprophylaxis trials in tuberculosis: a general review. Adv Tuberc Res: 1967; 17 29 105
33. Comstock G. W., Baum C., Snider D. E. Jr. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis: 1979; 119 5 827 830
34. Egsmose T., Ang'awa J. O., Poti S. J. The use of isoniazid among household contacts of open cases of pulmonary tuberculosis. Bull World Health Organ: 1965; 33 3 419 433
35. Del Castillo H., Bautista L. D., Jacinto C. P., Lorenzo C. E., Lapuz S., Legaspi B. Chemoprophylaxis in the Philippines: a controlled pilot study among household contacts of tuberculosis cases. Bull Quezon Institute: 1965; 7 277 290
36. Veening G. JJ. Long term isoniazid prophylaxis: controlled trial on INH prophylaxis after recent tuberculin conversion in young adults. Bull Int Union Tuberc: 1968; 41 169 171
37. Falk A., Fuchs G. F. Prophylaxis with isoniazid in inactive tuberculosis: a Veterans Administration cooperative study XII. Chest: 1978; 73 1 44 48 (Pubitemid 8271998)
38. Thompson N. J. International Union Against Tuberculosis Committee on Prophylaxis Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ: 1982; 60 4 555 564
39. Snider D. E. Jr, Caras G. J., Koplan J. P. Preventive therapy with isoniazid: cost-effectiveness of different durations of therapy. JAMA: 1986; 255 12 1579 1583 (Pubitemid 16167478)
40. Comstock G. W. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis: 1999; 3 10 847 850 (Pubitemid 29488035)
41. Centers for Disease Control and Prevention, American Thoracic Society, IDSA Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep: 2000; 49 RR-6 RR-6, No. RR-6 1 51
42. Polesky A., Farber H. W., Gottlieb D. J., et al. Rifampin preventive therapy for tuberculosis in Boston's homeless. Am J Respir Crit Care Med: 1996; 154 5 1473 1477 (Pubitemid 26391200)
43. Villarino M. E., Ridzon R., Weismuller P. C., et al. Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. Am J Respir Crit Care Med: 1997; 155 5 1735 1738 (Pubitemid 27216686)
44. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. Am Rev Respir Dis: 1992; 145 1 36 41
45. Page K. R., Sifakis F., Montes de Oca R., et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med: 2006; 166 17 1863 1870 (Pubitemid 44455169)
46. Li J., Munsiff S. S., Tarantino T., Dorsinville M. Adherence to treatment of latent tuberculosis infection in a clinical population in New York City. Int J Infect Dis: 2010; 14 4 e292 e297
47. Haley C. A., Stephan S., Vossel L. F., Sherfy E. A., Laserson K. F., Kainer M. A. Successful use of rifampicin for Hispanic foreign-born patients with latent tuberculosis infection. Int J Tuberc Lung Dis: 2008; 12 2 160 167 (Pubitemid 351212407)
48. Lardizabal A., Passannante M., Kojakali F., Hayden C., Reichman L. B. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest: 2006; 130 6 1712 1717 (Pubitemid 46033423)
49. Menzies D., Dion M. J., Rabinovitch B., Mannix S., Brassard P., Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med: 2004; 170 4 445 449 (Pubitemid 39214621)
50. Menzies D., Long R., Trajman A., et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med: 2008; 149 10 689 697
51. Aspler A., Long R., Trajman A., et al. Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB. Thorax: 2010; 65 7 582 587
52. Esfahani K., Aspler A., Menzies D., Schwartzman K. Potential cost-effectiveness of rifampin vs. isoniazid for latent tuberculosis: implications for future clinical trials. Int J Tuberc Lung Dis: 2011; 15 10 1340 1346
53. National Library of Medicine. Randomized clinical trial comparing 4RIF vs. 9INH for LTBI treatment-effectiveness. Registered at www.ClinicalTrials.gov as NCT00931736. Accessed April 12, 2012
54. Ormerod L. P. Reduced incidence of tuberculosis by prophylactic chemotherapy in subjects showing strong reactions to tuberculin testing. Arch Dis Child: 1987; 62 10 1005 1008 (Pubitemid 17155045)
55. Ormerod L. P. Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis. Arch Dis Child: 1998; 78 2 169 171 (Pubitemid 28136204)
56. Bright-Thomas R., Nandwani S., Smith J., Morris J. A., Ormerod L. P. Effectiveness of 3 months of rifampicin and isoniazid chemoprophylaxis for the treatment of latent tuberculosis infection in children. Arch Dis Child: 2010; 95 8 600 602
57. Martínez Alfaro E., Solera J., Serna E., et al. Compliance, tolerance and effectiveness of a short chemoprophylaxis regimen for the treatment of tuberculosis [in Spanish]. Med Clin (Barc): 1998; 111 11 401 404 (Pubitemid 28538085)
58. Geijo M. P., Herranz C. R., Vaño D., García A. J., García M., Dimas J. F. Short-course isoniazid and rifampin compared with isoniazid for latent tuberculosis infection: a randomized clinical trial [in Spanish]. Enferm Infecc Microbiol Clin: 2007; 25 5 300 304 (Pubitemid 47202767)
59. Spyridis N. P., Spyridis P. G., Gelesme A., et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis: 2007; 45 6 715 722 (Pubitemid 47378885)
60. Martínez Alfaro E. M., Cuadra F., Solera J., et al. The GECMEI Group Evaluation of 2 tuberculosis chemoprophylaxis regimens in patients infected with human immunodeficiency virus [in Spanish]. Med Clin (Barc): 2000; 115 5 161 165
61. Rivero A., López-Cortés L., Castillo R., et al. Grupo Andaluz para el estudio de las Enfermedades Infecciosas (GAEI) Randomized clinical trial investigating three chemoprophylaxis regimens for latent tuberculosis infection in HIV-infected patients [in Spanish]. Enferm Infecc Microbiol Clin: 2007; 25 5 305 310 (Pubitemid 47202768)
62. Rivero A., López-Cortés L., Castillo R., et al. Grupo Andaluz para el estudio de las Enfermedades Infecciosas (GAEI) Randomized trial of three regimens to prevent tuberculosis in HIV-infected patients with anergy [in Spanish]. Enferm Infecc Microbiol Clin: 2003; 21 6 287 292 (Pubitemid 36869935)
63. Whalen C. C., Johnson J. L., Okwera A., et al. Uganda-Case Western Reserve University Research Collaboration A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med: 1997; 337 12 801 808 (Pubitemid 27391629)
64. Martinson N. A., Barnes G. L., Moulton L. H., et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med: 2011; 365 1 11 20
65. Lecoeur H. F., Truffot-Pernot C., Grosset J. H. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis: 1989; 140 5 1189 1193 (Pubitemid 19276194)
66. Fox W., Ellard G. A., Mitchison D. A. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis: 1999; 3 10 02 S231 S279 (Pubitemid 29481843)
67. Halsey N. A., Coberly J. S., Desormeaux J., et al. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet: 1998; 351 9105 786 792 (Pubitemid 28112340)
68. Mwinga A., Hosp M., Godfrey-Faussett P., et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS: 1998; 12 18 2447 2457 (Pubitemid 28558603)
69. Quigley M. A., Mwinga A., Hosp M., Lisse I., Fuchs D., Godfrey-Faussett P., Porter J. DH. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS: 2001; 15 2 215 222 (Pubitemid 32142297)
70. Gordin F., Chaisson R. E., Matts J. P., et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. JAMA: 2000; 283 11 1445 1450
71. Centers for Disease Control and Prevention (CDC) Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection-New York and Georgia, 2000. MMWR Morb Mortal Wkly Rep: 2001; 50 15 289 291
72. Centers for Disease Control and Prevention (CDC) Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations-United States, 2001. MMWR Morb Mortal Wkly Rep: 2001; 50 34 733 735
73. Centers for Disease Control and Prevention (CDC) Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection. MMWR Morb Mortal Wkly Rep: 2002; 51 44 998 999
74. Ijaz K., Jereb J. A., Lambert L. A., et al. Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis infection. Clin Infect Dis: 2006; 42 3 346 355 (Pubitemid 43122309)
75. McElroy P. D., Ijaz K., Lambert L. A., et al. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection. Clin Infect Dis: 2005; 41 8 1125 1133 (Pubitemid 41429475)
76. Centers for Disease Control and Prevention (CDC); American Thoracic Society Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States, 2003. MMWR Morb Mortal Wkly Rep: 2003; 52 31 735 739
77. Schechter M., Zajdenverg R., Falco G., et al. Weekly rifapentine/ isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med: 2006; 173 8 922 926
78. Martinson N. A., Barnes G. L., Moulton L. H., et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med: 2011; 365 1 11 20
79. Sterling T. R., Villarino M. E., Borisov A. S., et al. Three months of once-weekly rifapentine and isoniazid for M. tuberculosis infection. N Engl J Med: 2011; 365 23 2155 2166
80. Ji B., Truffot-Pernot C., Lacroix C., et al. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis: 1993; 148 6 Pt 1 1541 1546 (Pubitemid 24002484)
81. Chapuis L., Ji B., Truffot-Pernot C., O'Brien R. J., Raviglione M. C., Grosset J. H. Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. Am J Respir Crit Care Med: 1994; 150 5 Pt 1 1355 1362 (Pubitemid 24356652)
82. Miyazaki E., Chaisson R. E., Bishai W. R. Analysis of rifapentine for preventive therapy in the Cornell mouse model of latent tuberculosis. Antimicrob Agents Chemother: 1999; 43 9 2126 2130 (Pubitemid 29421188)
83. Nuermberger E., Tyagi S., Williams K. N., Rosenthal I., Bishai W. R., Grosset J. H. Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model. Am J Respir Crit Care Med: 2005; 172 11 1452 1456 (Pubitemid 43069820)
84. Kritski A. L., Marques M. JO, Rabahi M. F., et al. Transmission of tuberculosis to close contacts of patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med: 1996; 153 1 331 335
85. Vernon A., Burman W., Benator D., Khan A., Bozeman L. Tuberculosis Trials Consortium Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet: 1999; 353 9167 1843 1847 (Pubitemid 29251017)
86. Sterling T., Benson C., Shang N., et al. AIDS Clinical Trials Group, Tuberculosis Trials Consortium Tolerability among HIV-positive persons of three months of once-weekly rifapentine + INH (3HP) versus 9 months of daily INH (9H) for treatment of latent tuberculosis infection: the PREVENT TB Study (TBTC Study 26/ACTG 5259). MOAB0302-Oral Abstract, presented at the 19th International AIDS Conference, Washington DC, July 2012. http://pag.aids2012.org/Abstracts.aspx? SID=211&AID=5981. Accessed September 20, 2012
87. Villarino M. E., Scott N., Weis S., et al, IMPAACT, and the Tuberculosis Trials Consortium Tolerability among children of three months of once-weekly rifapentine + INH (3HP) vs. 9 months of daily INH (9H) for treatment of latent tuberculosis infection: The PREVENT TB Study (TBTC Study 26/ACTG 5259). Oral abstract 1323. Paper presented at: Infectious Disease Society of America (IDSA); October 20, 2012; San Diego, CA. Available at: https://idsa.confex.com/idsa/ 2012/. Accessed: November 20, 2012
88. Girling D. J., Hitze K. L. Adverse reactions to rifampicin in antituberculosis regimens. J Antimicrob Chemother: 1977; 3 2 115 132 (Pubitemid 8065987)
89. Forget E. J., Menzies D. Adverse reactions to first-line antituberculosis drugs. Expert Opin Drug Saf: 2006; 5 2 231 249 (Pubitemid 43379622)
90. Matteelli A., Olliaro P., Signorini L., et al. Tolerability of twice-weekly rifabutin-isoniazid combinations versus daily isoniazid for latent tuberculosis in HIV-infected subjects: a pilot study. Int J Tuberc Lung Dis: 1999; 3 11 1043 1046
91. Dietze R., Teixeira L., Rocha L. M., et al. Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis. Antimicrob Agents Chemother: 2001; 45 7 1972 1976 (Pubitemid 32591685)
92. Centers for Disease Control and Prevention (CDC) Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep: 2011; 60 48 1650 1653
93. Centers for Disease Control and Prevention (CDC) Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection-United States, 2004-2008. MMWR Morb Mortal Wkly Rep: 2010; 59 8 224 229
94. Evaluating the safety and effectiveness of short-course rifapentine/isoniazid for the prevention of active tuberculosis in HIV-infected individuals with latent tuberculosis infection. http://www.clinicaltrials.gov/ ct2/show/NCT01404312?term=tuberculosis%2C+rifapentine%2C+actg&rank=1. Accessed September 30, 2012
95. Garibaldi R. A., Drusin R. E., Ferebee S. H., Gregg M. B. Isoniazid-associated hepatitis: report of an outbreak. Am Rev Respir Dis: 1972; 106 3 357 365
96. American Thoracic Society, National Tuberculosis and Respiratory Disease Association, Center for Disease Control Preventive treatment of tuberculosis. Am Rev Respir Dis: 1971; 104 3 460 463
97. Centers for Disease Control, U.S. Dept of Health Education and Welfare Isoniazid and liver disease: report of the ad hoc committee on isoniazid and liver disease. Am Rev Respir Dis: 1971; 104 454
98. Kopanoff D. E., Snider D. E. Jr, Caras G. J. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis: 1978; 117 6 991 1001 (Pubitemid 8380195)
99. American Thoracic Society, American Lung Association, Center for Disease Control Preventive therapy of tuberculous infection. Am Rev Respir Dis: 1974; 110 3 371 374
100. Taylor W. C., Aronson M. D., Delbanco T. L. Should young adults with a positive tuberculin test take isoniazid? Ann Intern Med: 1981; 94 6 808 813 (Pubitemid 11123384)
101. Rose D. N., Schechter C. B., Fahs M. C., Silver A. L. Tuberculosis prevention: cost-effectiveness analysis of isoniazid chemoprophylaxis. Am J Prev Med: 1988; 4 2 102 109
102. Colice G. L. Decision analysis, public health policy, and isoniazid chemoprophylaxis for young adult tuberculin skin reactors. Arch Intern Med: 1990; 150 12 2517 2522
103. Rose D. N., Schechter C. B., Silver A. L. The age threshold for isoniazid chemoprophylaxis: a decision analysis for low-risk tuberculin reactors. JAMA: 1986; 256 19 2709 2713 (Pubitemid 17178087)
104. Salpeter S. R., Sanders G. D., Salpeter E. E., Owens D. K. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis. Ann Intern Med: 1997; 127 12 1051 1061 (Pubitemid 28012074)
105. American Thoracic Society, Centers for Disease Control and Prevention Treatment of tuberculosis and other mycobacterial diseases. Am Rev Respir Dis: 1983; 127 6 790 796
106. Snider D. E. Jr, Caras G. J., Koplan J. P. Preventive therapy with isoniazid: cost-effectiveness of different durations of therapy. JAMA: 1986; 255 12 1579 1583 (Pubitemid 16167478)
107. Salpeter S. R. Fatal isoniazid-induced hepatitis: its risk during chemoprophylaxis. West J Med: 1993; 159 5 560 564 (Pubitemid 23339480)
108. Millard P. S., Wilcosky T. C., Reade-Christopher S. J., Weber D. J. Isoniazid-related fatal hepatitis. West J Med: 1996; 164 6 486 491 (Pubitemid 26250847)
109. Wu S. S., Chao C. S., Vargas J. H., et al. Isoniazid-related hepatic failure in children: a survey of liver transplantation centers. Transplantation: 2007; 84 2 173 179 (Pubitemid 47205750)
110. Nolan C. M., Goldberg S. V., Buskin S. E. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA: 1999; 281 11 1014 1018 (Pubitemid 29143893)
111. Saukkonen J. J., Cohn D. L., Jasmer R. M., et al. ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med: 2006; 174 8 935 952 (Pubitemid 44564795)
112. Centers for Disease Control and Prevention (CDC) Severe isoniazid-associated hepatitis-New York, 1991-1993. MMWR Morb Mortal Wkly Rep: 1993; 42 28 545 547
113. Yee D., Valiquette C., Pelletier M., Parisien I., Rocher I., Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med: 2003; 167 11 1472 1477 (Pubitemid 37363354)
114. Smith B. M., Schwartzman K., Bartlett G., Menzies D. Adverse events associated with treatment of latent tuberculosis in the general population. CMAJ: 2011; 183 3 E173 E179
115. Wen X., Wang J. S., Neuvonen P. J., Backman J. T. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. Eur J Clin Pharmacol: 2002; 57 11 799 804 (Pubitemid 34143338)
116. Centers for Disease Control & Prevention Treatement of tuberculosis. American Thoracic Society, CDC, and Infectious Diseases Society of America. MMWR Recomm Rep: 2003; 52 RR-11 1 77
117. Grosset J., Leventis S. Adverse effects of rifampin. Rev Infect Dis: 1983; 5 03 S440 S450
118. Aquinas M., Allan W. GL, Horsfall P. A., et al. Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong. BMJ: 1972; 1 5803 765 771
119. Singapore Tuberculosis Service/British Medical Research Council Controlled trial of intermittent regimens of rifampin plus isoniazid for pulmonary tuberculosis in Singapore: the results up to 30 months. Am Rev Respir Dis: 1977; 116 5 807 820
120. Rose D. N. Short-course prophylaxis against tuberculosis in HIV-infected persons: a decision and cost-effectiveness analysis. Ann Intern Med: 1998; 129 10 779 786 (Pubitemid 28522812)
121. Perlman D. C., Gourevitch M. N., Trinh C., Salomon N., Horn L., Des Jarlais D. C. Cost-effectiveness of tuberculosis screening and observed preventive therapy for active drug injectors at a syringe-exchange program. J Urban Health: 2001; 78 3 550 567 (Pubitemid 32852792)
122. Snyder D. C., Paz E. A., Mohle-Boetani J. C., Fallstad R., Black R. L., Chin D. P. Tuberculosis prevention in methadone maintenance clinics: effectiveness and cost-effectiveness. Am J Respir Crit Care Med: 1999; 160 1 178 185 (Pubitemid 29326085)
123. Mohle-Boetani J. C., Miller B., Halpern M., et al. School-based screening for tuberculous infection: a cost-benefit analysis. JAMA: 1995; 274 8 613 619
124. Tan M. C., Marra C. A., Sadatsafavi M., et al. Cost-effectiveness of LTBI treatment for TB contacts in British Columbia. Value Health: 2008; 11 5 842 852
125. Rose D. N., Schechter C. B., Fahs M. C., Silver A. L. Tuberculosis prevention: cost-effectiveness analysis of isoniazid chemoprophylaxis. Am J Prev Med: 1988; 4 2 102 109
126. Aspler A., Long R., Trajman A., et al. Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB. Thorax: 2010; 65 7 582 587
127. Esfahani K., Aspler A., Menzies D., Schwartzman K. Potential cost-effectiveness of rifampin vs. isoniazid for latent tuberculosis: implications for future clinical trials. Int J Tuberc Lung Dis: 2011; 15 10 1340 1346
128. Ziakas P. D., Mylonakis E. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin Infect Dis: 2009; 49 12 1883 1889
129. Holland D. P., Sanders G. D., Hamilton C. D., Stout J. E. Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. Am J Respir Crit Care Med: 2009; 179 11 1055 1060
130. Holland D. P., Sanders G. D., Hamilton C. D., Stout J. E. Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection. PLoS ONE: 2011; 6 7 e22276
131. Chavan S., Newlands D., Smith C. A systematic review of economic evaluations of chemoprophylaxis for tuberculosis. J Trop Med: 2011; 2011 130976 10.1155/2011/130976
132. Pitchenik A. E., Cole C., Russell B. W., Fischl M. A., Spira T. J., Snider D. E. Jr. Tuberculosis, atypical mycobacteriosis, and the acquired immunodeficiency syndrome among Haitian and non-Haitian patients in south Florida. Ann Intern Med: 1984; 101 5 641 645 (Pubitemid 15223305)
133. Pape J. W., Jean S. S., Ho J. L., Hafner A., Johnson W. D. Jr. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet: 1993; 342 8866 268 272 (Pubitemid 23224420)
134. Graham N. MH, Galai N., Nelson K. E., et al. Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease. Arch Intern Med: 1996; 156 8 889 894 (Pubitemid 26119816)
135. Akolo C., Adetifa I., Shepperd S., Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev: 2010; 1 CD000171
136. Hawken M. P., Meme H. K., Elliott L. C., et al. Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. AIDS: 1997; 11 7 875 882 (Pubitemid 27226410)
137. Fitzgerald D. W., Severe P., Joseph P., et al. No effect of isoniazid prophylaxis for purified protein derivative-negative HIV-infected adults living in a country with endemic tuberculosis: results of a randomized trial. J Acquir Immune Defic Syndr: 2001; 28 3 305 307 (Pubitemid 33055460)
138. Gordin F. M., Matts J. P., Miller C., et al. Terry Beirn Community Programs for Clinical Research on AIDS A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. N Engl J Med: 1997; 337 5 315 320 (Pubitemid 27318993)
139. Lim H. J., Okwera A., Mayanja-Kizza H., Ellner J. J., Mugerwa R. D., Whalen C. C. Effect of tuberculosis preventive therapy on HIV disease progression and survival in HIV-infected adults. HIV Clin Trials: 2006; 7 4 172 183 (Pubitemid 44717781)
140. Churchyard G. J., Scano F., Grant A. D., Chaisson R. E. Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities. J Infect Dis: 2007; 196 01 S52 S62 (Pubitemid 47206085)
141. Mohammed A., Myer L., Ehrlich R., Wood R., Cilliers F., Maartens G. Randomised controlled trial of isoniazid preventive therapy in South African adults with advanced HIV disease. Int J Tuberc Lung Dis: 2007; 11 10 1114 1120 (Pubitemid 47605402)
142. Watkins R. E., Brennan R., Plant A. J. Tuberculin reactivity and the risk of tuberculosis: a review. Int J Tuberc Lung Dis: 2000; 4 10 895 903
143. Samandari T., Agizew T. B., Nyirenda S., et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet: 2011; 377 9777 1588 1598
144. World Health Organization Guidelines for intensified tuberculosis case finding and isoniazid preventive therapy for people living with HIV in resource constrained settings. Geneva, Switzerland; 2011. http://www.stoptb.org/wg/tb- hiv/assets/documents/9789241500708-eng.pdf. Accessed September 30, 2012
145. Suthar A. B., Lawn S. D., del Amo J., et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med: 2012; 9 7 e1001270 10.1371/journal.pmed.1001270
146. Gupta A., Wood R., Kaplan R., Bekker L-G, Lawn S. D. Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community. PLoS ONE: 2012; 7 3 e34156 10.1371/journal.pone.0034156
147. Rangaka M. X., Boulle A., Wilkinson R. J., et al. Randomized controlled trial of isoniazid preventive therapy in HIV-infected persons on antiretroviral therapy in South Africa. Oral late breaker presented 26 July: 2012; at the International AIDS Conference, Washington, DC. Abstract. http://pag.aids2012. org/Abstracts.aspx?SID=16&AID=21471. Accessed September 30, 2012
148. Fitzgerald D. W., Desvarieux M., Severe P., Joseph P., Johnson W. D. Jr, Pape J. W. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. Lancet: 2000; 356 9240 1470 1474
149. Perriëns J. H., St Louis M. E., Mukadi Y. B., et al. Pulmonary tuberculosis in HIV-infected patients in Zaire: a controlled trial of treatment for either 6 or 12 months. N Engl J Med: 1995; 332 12 779 784
150. Create project. Available at: http://www.tbhiv-create.org/#. Accessed May 27, 2012
151. Churchyard G., Fielding K., Lewis J., et al. on behalf of the Thibela TB Team Community-wide isoniazid preventive therapy does not improve TB control among gold miners: the Thibela TB Study, South Africa. Abstract 149bLB; and Fielding K, Grant A, Lewis J, Hayes R, and Churchyard G. Individual-level effect of isoniazid preventive therapy on risk of TB: the Thibela TB Study. Abstract 150bLB. 19th CROI, Seattle, WA, March 2012. http://app2.capitalreach.com/ esp1204/servlet/tc?c=10164&cn=retro&s=20481&&dp=player. jsp&e=16642&mediaType=slideVideo. Accessed September 20, 2012
152. Muyoyeta M. The ZAMSTAR Study Team Impact of ZAMSTAR interventions on prevalence of culture-positive tuberculosis; and Shanaube K; The ZAMSTAR Study Team. Impact of ZAMSTAR interventions on transmission of tuberculosis; presented at IUATLD World Lung Health Conference, Lille FR, 30 October 2011 http://uwclh.conference2web.com/content/1060. Accessed September 20, 2012
153. Durovni B., Saraceni V., Pacheco A., et al. Impact of tuberculosis (TB) screening and isoniazid preventive therapy (IPT) on incidence of TB and death in the TB/HIV in Rio de Janeiro (THRio) study. 6th IAS Conference on HIV Pathogenesis and Treatment, Rome, 2011 Abstract no. WELBB02; and Durovni B, Saraceni V, Pacheco A, Cavalcante S, Cohn S, King B, Efron A, Moulton Chaisson R, Golub J, THRio study group. Impact of tuberculosis screening and isoniazid preventive therapy on incidence of TB and death in the TB/HIV in Rio de Janeiro (THRio) study presented at the 19th International AIDS Conference, Washington, DC; July 2012. Abstract WEPE067. http://pag.aids2012.org/abstracts.aspx?aid= 13895. Accessed September 20, 2012
154. Balcells M. E., Thomas S. L., Godfrey-Faussett P., Grant A. D. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis: 2006; 12 5 744 751 (Pubitemid 43726847)
155. Fraser A., Paul M., Attamna A., Leibovici L. Drugs for preventing tuberculosis in people at risk of multiple-drug-resistant pulmonary tuberculosis. Cochrane Database Syst Rev: 2006; 2 2, Issue 2 CD005435 10.1002/14651858.CD005435.pub2
156. Fraser A., Paul M., Attamna A., Leibovici L. Treatment of latent tuberculosis in persons at risk for multidrug-resistant tuberculosis: systematic review. Int J Tuberc Lung Dis: 2006; 10 1 19 23 (Pubitemid 43266272)
157. Williams K., Minkowski A., Amoabeng O., et al. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother: 2012; 56 6 3114 3120
158. Diacon A. H., Donald P. R., Pym A., et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother: 2012; 56 6 3271 3276
159. Holland D. P., Sanders G. D., Hamilton C. D., Stout J. E. Strategies for treating latent multiple-drug resistant tuberculosis: a decision analysis. PLoS ONE: 2012; 7 1 e30194
160. Keane J., Gershon S., Wise R. P., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med: 2001; 345 15 1098 1104
161. Centers for Disease Control and Prevention (CDC) Tuberculosis associated with blocking agents against tumor necrosis factor-alpha-California, 2002-2003. MMWR Morb Mortal Wkly Rep: 2004; 53 30 683 686
162. Solovic I., Sester M., Gomez-Reino J. J., et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J: 2010; 36 5 1185 1206
163. Tortajada C., Martínez-Lacasa J., Sánchez F., et al. Tuberculosis Prevention Working Group Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus? Int J Tuberc Lung Dis: 2005; 9 3 276 281 (Pubitemid 40392942)
164. van Hest R., Baars H., Kik S., et al. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment. Clin Infect Dis: 2004; 39 4 488 496 (Pubitemid 39120923)
165. Leung C. C., Law W. S., Chang K. C., et al. Initial experience on rifampin and pyrazinamide vs isoniazid in the treatment of latent tuberculosis infection among patients with silicosis in Hong Kong. Chest: 2003; 124 6 2112 2118 (Pubitemid 38010577)
166. McNeill L., Allen M., Estrada C., Cook P.; McNeillL. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity. Chest: 2003; 123 1 102 106 (Pubitemid 36126720)
167. Jasmer R. M., Saukkonen J. J., Blumberg H. M., et al. Short-Course Rifampin and Pyrazinamide for Tuberculosis Infection (SCRIPT) Study Investigators Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med: 2002; 137 8 640 647 (Pubitemid 35176096)
168. Narita M., Kellman M., Franchini D. L., McMillan M. E., Hollender E. S., Ashkin D. Short-course rifamycin and pyrazinamide treatment for latent tuberculosis infection in patients with HIV infection: the 2-year experience of a comprehensive community-based program in Broward County, Florida. Chest: 2002; 122 4 1292 1298 (Pubitemid 35339543)
169. Madhi S. A., Nachman S., Violari A., et al. P1041 Study Team Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. N Engl J Med: 2011; 365 1 21 31
170. McNab B. D., Marciniuk D. D., Alvi R. A., Tan L., Hoeppner V. H. Twice weekly isoniazid and rifampin treatment of latent tuberculosis infection in Canadian plains Aborigines. Am J Respir Crit Care Med: 2000; 162 3 Pt 1 989 993
171. Zar H. J., Cotton M. F., Strauss S., et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ: 2007; 334 7585 136
172. Jasmer R. M., Snyder D. C., Chin D. P., et al. Twelve months of isoniazid compared with four months of isoniazid and rifampin for persons with radiographic evidence of previous tuberculosis: an outcome and cost-effectiveness analysis. Am J Respir Crit Care Med: 2000; 162 5 1648 1652
173. Geiter L. J. Results of a randomized controlled trial to assess the toxicity and patient adherence with two short-course regimens for the prevention of tuberculosis, a two-month regimen of rifampin and pyrazinamide or a four-month regimen of rifampin only, in comparison with a control regimen of six-months-isoniazid. Diss., Johns Hopkins School of Hygiene and Public Health, Baltimore, MD, 1997. UMI 9730708
174. Hawken M. P., Meme H. K., Elliott L. C., et al. Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. AIDS: 1997; 11 7 875 882 (Pubitemid 27226410)
175. Graczy K. J., O'Brien R. J., Bek E., et al. Assessment of rifampin containing regimens for tuberculosis preventive therapy: preliminary results of a pilot study in Poland. Am Rev Respir Dis: 1991; 143 A119
176. TBTC Study 26 assumed a background rate of 5% TB disease in high risk persons with LTBI; the rate observed in those receiving little or no therapy was only 1.6%. TBESC Task Order 2 has reported that many associated cases have already occurred by the time the contact investigation is implemented (Reichler M, et al. manuscript submitted)
177. Hill A. N., Becerra J. E., Castro K. G. Modelling tuberculosis trends in the USA. Epidemiol Infect: 2012; 140 10 1862 1872